AOD9604 Specification and Vial Format Review: practical notes on ordering AOD9604 (2mg / 5mg / 10mg) for Metabolic Research work through sulanpeptide.vip.
AOD9604 is a synthetic peptide analog derived from the C-terminal region of human growth hormone. It is used in laboratory research on lipid-metabolism signaling, GH-fragment structure-activity relationships, and peptide pathways involved in metabolic regulation.
Glycerol release assays, adipocyte differentiation timelines, and receptor-binding competition experiments appear frequently in fragment-peptide research papers. Early patent and academic literature positioned AOD9604 analogs as tools for dissecting GH fragment biology separate from IGF-1 mediated growth signaling.
AOD9604 corresponds to a modified fragment of the GH polypeptide C-terminal region studied for lipolytic signaling in adipocyte models without full GH receptor activation. Research literature examines β3-adrenergic pathway cross-talk and fat-cell lipolysis markers in vitro when adipocyte lines are exposed to fragment analogs.
Side-by-side review of specification table, vial label, and COA prevents release errors for AOD9604. Principal investigators should sign off AOD9604 SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (2mg / 5mg / 10mg) in procurement systems—do not round kit counts.
Catalog identifiers for AOD9604: CAS 221231-10-3, Formula: C78H123N23O23S2. MW 1815.1 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for AOD9604 to support reproducibility.
Dose planning for AOD9604 should state mass (2mg / 5mg / 10mg) or molarity derived from catalog molecular weight.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for AOD9604 should state whether the lot COA must meet or exceed that threshold for your Metabolic Research assay type. Specification alignment for AOD9604 requires copying exact kit notation (2mg / 5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for AOD9604—CAS 221231-10-3, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing AOD9604 should include these fields for reproducibility in Metabolic Research journals. Format selection for AOD9604 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for AOD9604. QA sign-off should reference all four documents in the batch record.
Format selection for AOD9604 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for AOD9604. QA sign-off should reference all four documents in the batch record.
Molecular identifiers for AOD9604—CAS 221231-10-3, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing AOD9604 should include these fields for reproducibility in Metabolic Research journals.
AOD9604 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.